Region

The MENA Region has drawn a lot of interest in the pharmaceutical industry in recent years, principally due to huge investment in both the private and public sectors; the introduction of mass health insurance and several moves to liberalize national economies. Egypt, Saudi Arabia, Algeria, Jordan, U.A.E, Lebanon and Kuwait are some of the major markets in the Region.

The MENA region will remain one of the fastest growing regions in the world over the next few years due to:

• Significant government spending on infrastructure
• A very young and fast-growing population
• Increasing flow of private investment as more of these emerging markets open
• Increasing access to innovative new medicines due to the rise in chronic diseases and increased coverage of health insurance

The Region includes a mix of relatively wealthy but not-yet-saturated markets, fast-growing emerging markets, and a number of under-developed markets which together result in long-term growth prospects within the Region.

Vie Pharma utilizes its regional network to partner with companies to seize the opportunity of entering the fastest-growing markets in the Region, whilst helping to balance the risk that is often associated with doing business in new territories.

Strategy

Our path at Vie Pharma is defined by three strategic imperatives:

1. Be the partner-of-choice and licensee for research-based pharmaceutics, biologics, and genomic companies seeking to market their FDA and EMEA/European approved products in the EMEA Region; and providing them with a “one-stop” and complete regional solution.
2. Be the preferred partner for existing pharmaceutical companies in the region who solicit the services of Vie Pharma to further their brand equity and maintain their presence in the region.
3. Introduce Vie Pharma’s own propriety brands complementary to our core business model and our existing portfolio.